1. 527 FRAILTY AND MULTIMORBIDITY IN TYPE 2 DIABETES: A UK BIOBANK ANALYSIS
- Author
-
James Lewsey, David A. McAllister, Frances S. Mair, Elaine Butterly, Bhautesh Dinesh Jani, Barbara I. Nicholl, and Peter Hanlon
- Subjects
Aging ,medicine.medical_specialty ,business.industry ,Cancer ,General Medicine ,Type 2 diabetes ,Hypoglycemia ,medicine.disease ,Comorbidity ,Biobank ,Internal medicine ,medicine ,Multimorbidity ,Frail elderly ,Middle-aged adult ,Geriatrics and Gerontology ,business - Abstract
Introduction Frailty and multimorbidity are common in type 2 diabetes (T2D), including people Methods Analysis of UK Biobank participants (n = 20,566) with T2D aged 40-72 years comparing two frailty measures (frailty phenotype and frailty index) and two multimorbidity measures (Charlson comorbidity index and a simply count of 40 long-term conditions (LTCs)). Outomes: mortality (all-cause, cardiovascular- and cancer-related mortality), Major Adverse Cardiovascular Event (MACE), hospitalization with hypoglycaemia or fall/fracture. Results Measure choice influenced the population identified: 42% of participants were identified as frail/multimorbid by at least one measure; only 2.2% were identified by all four measures. Both frailty and multimorbidity, by all measures, were prevalent throughout the age range studied. Each measure was associated with mortality, MACE, hypoglycaemia and falls. The absolute 5-year mortality risk was higher in older versus younger participants with a given level of frailty (e.g. 1.9%, and 9.9% in men aged 45 and 65, respectively, using frailty phenotype) or multimorbidity (e.g. 1.3%, and 7.8% in men with 4 LTCs aged 45 and 65, respectively). Using frailty phenotype, the relationship between higher HbA1c and mortality was stronger in frail compared with pre-frail or robust participants. Conclusion Assessment of frailty/multimorbidity should be embedded within routine management of middle-aged and older people with T2D. Method of identification as well as features such as age impact baseline risk and should influence clinical decisions (e.g. glycaemic control). more...
- Published
- 2021
- Full Text
- View/download PDF